# Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study

> **NCT06177691** · — · UNKNOWN · sponsor: **Jaeb Center for Health Research** · enrollment: 77 (actual)

## Conditions studied

- Type1 Diabetes

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06177691
- **Lead sponsor:** Jaeb Center for Health Research
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-07
- **Primary completion:** 2025-12-18
- **Final completion:** 2025-12-18
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2023-12-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06177691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06177691, "Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06177691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*